| Drug Name |
Betamethasone |
| Drug ID |
BADD_D00260 |
| Description |
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties.[A192444] It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders.[A192444] Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.[A192444] |
| Indications and Usage |
Systemic use: for the treatment of edocrine disorders, rheumatic disorders, collagen diseases, dermatological diseases, allergic states, ophthalmic diseases, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, gastrointestinal diseases, tuberculous meningitis and trichinosis. |
| Marketing Status |
Discontinued |
| ATC Code |
A07EA04; C05AA05; D07AC01; D07XC01; H02AB01; R01AD06; R03BA04; S01BA06; S01CB04; S02BA07; S03BA03 |
| DrugBank ID |
DB00443
|
| KEGG ID |
D00244
|
| MeSH ID |
D001623
|
| PubChem ID |
9782
|
| TTD Drug ID |
D0CW1P
|
| NDC Product Code |
52128-166; 22552-0030; 64958-0012 |
| Synonyms |
Betamethasone | Flubenisolone | Betadexamethasone | Celestona | Cellestoderm | Celeston | Celestone |
